The motivation for this work is the expression of CD59 in AQP4-expressing cells in the central nervous system and in the periphery, and our prior data showing that CD59−/− mice are highly sensitive to development of NMO pathology following direct administration of AQP4-IgG and human complement into brain or cerebrospinal fluid [33]. This evidence concerns the gene AQP4 and neuromyelitis optica.